 This study proposes a new approach to developing allogeneic car T-cell therapies. The researchers used CRSPR, CAS9 gene editing to create human hypoimmune, hip, T-cells which lack certain genetic components that can cause immune rejection. They then added two additional genes CD47 targeting an anti-CD19 car to these hip T-cells to make them more effective against cancer. The results show that this combination of genetic modifications does not impair the ability of the T-cells to kill cancer cells, but instead enhances their effectiveness. This could lead to the development of universal allogeneic car T-cell therapies that can be used to treat a wide range of cancers. This article was authored by Xiaoming Hu, Carl Manor, Rowena De Jesus, and others.